Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Files NIPT Patent Infringement Suit Against Genoma in Switzerland

NEW YORK (GenomeWeb) – Illumina is suing Swiss non-invasive prenatal testing firm Genoma for patent infringement.

On behalf of its fully-owned, NIPT-focused subsidiary Verinata Health, Illumina has filed suit against Genoma in Switzerland's Federal Patent Court. In a statement, Illumina said it is seeking all available remedies including damages and injunctive relief.

Illumina asserts that Genoma is infringing upon four European patents covering the use of cell-free fetal DNA for NIPT. Genoma's Tranquillty NIPT service is based on Premaitha Health's Iona Test, using next-generation sequencing to analyze cell-free DNA from maternal blood.

Since the beginning of 2015, Illumina has filed numerous lawsuits against companies in Europe alleging patent infringement. It has sued both Premaitha and Roche subsidiary Ariosa Diagnostics, which offers the Harmony NIPT test, along with several companies that offer NIPT services based on either the Iona test or the Harmony test.

And Illumina may not be finished filing such lawsuits. "We will continue to monitor activities in the NIPT field and file suits where appropriate to protect our substantial investments in this technology covered by our intellectual property," Illumina Senior VP and General Counsel Charles Dadswell said in a statement.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.